BGM Group Ltd
BGMHealthcare·Drug Manufacturers - Specialty & Generic·China·Micro·NASD·Nov 11 • 3:59 PM ET
8.05+0.04 (0.50%)
2026-11-12 04:33 CET
Market cap
106.97 USD m
Revenue, TTM
47.90 USD m
Net income, TTM
-21.18 USD m
Free cash flow, TTM
1.46 USD m
EPS diluted, TTM
-4.80
P/E
-
Price
BGM against its 20, 50 and 200-day averages2050200
97.3% under the 52-week high of 302.40 on 5 Nov 2025. 52-week low 6.45 on 1 Oct 2026. Last 15 sessions, 38.4% high to low
Volume 0.20× normal · the line is the 50-bar volume average
Profile
BGM52-week range, 1% of the way up
6.45291.3
BGM Group Ltd. is a holding company, which engages in the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. It operates through the following segments: Oxytetracycline and Licorice Products, and Traditional Chinese Medicine Derivatives (TCMD); Heparin Products and Sausage Casing; and Fertilizer. The Oxytetracycline and Licorice Products, and TCMD segment focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, and TCMD. The Heparin Products and Sausage Casing segment treats cardiovascular diseases, cerebrovascular diseases, and hemodialysis. The Fertilizer segment includes Xiongguan, Organic Fertilizer and Xiongguan, and Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.
| Employees | 471 |
|---|---|
| IPO | Jan 12, 2021 |
| Beta | 1.89 |
| ATR, 14d | 0.99 |
| Rel volume | 0.20 |
| Short float | 0.20% |
| Insider own | 72.48% |
| Inst own | 0.05% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 107.50M |
| Enterprise Value | 98.66M |
| Income | -21.18M |
| Sales | 47.90M |
| Book/sh | 59.55 |
| Cash/sh | 0.86 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 471 |
| IPO | Jan 12, 2021 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | 2.24 |
| P/B | 0.14 |
| P/C | 9.31 |
| P/FCF | 73.63 |
| EV/EBITDA | - |
| EV/Sales | 2.06 |
| Quick Ratio | 0.65 |
| Current Ratio | 1.25 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -4.80 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | - - |
| Sales past 3/5Y | -16.38% -5.39% |
| EPS Y/Y TTM | 43.66% |
| Sales Y/Y TTM | 78.43% |
| EPS Q/Q | 58.37% |
| Sales Q/Q | 69.76% |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 72.48% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 0.05% |
| Inst Trans | 0.37% |
| ROA | -6.58% |
| ROE | -7.30% |
| ROIC | -5.32% |
| Gross Margin | 12.81% |
| Oper. Margin | -23.42% |
| Profit Margin | -44.22% |
| SMA20 | -10.56% |
| SMA50 | -5.38% |
| SMA200 | -54.44% |
| Trades | - |
Technical
| Shs Outstand | 6.02M |
|---|---|
| Shs Float | 3.67M |
| Short Float | 0.20% |
| Short Ratio | 0.82 |
| Short Interest | 0.01M |
| 52W High | 291.30 -97.24% |
| 52W Low | 6.45 24.81% |
| Volatility | 4.80% 9.87% |
| ATR (14) | 0.99 |
| RSI (14) | 44.40 |
| Beta | 1.89 |
| Rel Volume | 0.20 |
| Avg Volume | 9.03K |
| Volume | 1,813 |
Performance
| Perf Week | -15.62% |
|---|---|
| Perf Month | -23.19% |
| Perf Quarter | -10.11% |
| Perf Half Y | 2.38% |
| Perf YTD | -92.73% |
| Perf Year | -97.20% |
| Perf 3Y | -87.49% |
| Perf 5Y | -98.42% |
| Perf 10Y | - |
| Recom | - |
| Target Price | - |
| Prev Close | 8.01 |
| Price | 8.05 |
| Change % | 0.50% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| CPHI | China Pharma Holdings Inc | 23.37M |
| PAHC | Phibro Animal Health Corp | 1.43B |
| UPC | Universe Pharmaceuticals INC | 7.89M |
| ZYBT | Zhengye Biotechnology Holding Ltd | 45.19M |
| SXTC | China SXT Pharmaceuticals Inc | 1.95M |
| ELAN | Elanco Animal Health Inc | 13.24B |
| ZTS | Zoetis Inc | 33.55B |
| WDH | Waterdrop Inc ADR | 280.69M |
| BON | Bon Natural Life Ltd | 9.32M |
| HUIZ | Huize Holding Ltd ADR | 18.83M |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| ONEQ | Fidelity Nasdaq Composite Index ETF | AUM: 10.35B |
News
latest 14 of 44- BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F (GlobeNewswire) +6.86%
- BGM Group Ltd. (BGM) Surges 35% as AI, Biopharma Transformation Gains Investor Attention (Insider Monkey)
- BGM To Report First Half 2025 Unaudited Financial Results on July 24, 2025 (PR Newswire)
- From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts (PR Newswire) -18.89% +20.35%
- BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem (PR Newswire)
- BGM Completes Acquisition of YX to Advance AI-Powered Intelligent Platform (PR Newswire)
- BGM Group Acquires Wonder Dragon to Accelerate 'Healthcare' Strategy (PR Newswire)
- BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform (PR Newswire)
- BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution (PR Newswire)
- BGM Group Establishes 'Duxiaobao Management Committee' to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry (PR Newswire)
- BMG Completed Acquisition of High-Quality Assets, Marking a New Chapter in Diversified Growth (PR Newswire)
- In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI (PR Newswire)
- AIX Completes Strategic Share Exchange with BGM to Drive Growth in AI Insurance and Healthcare (GlobeNewswire)
- BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development (PR Newswire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| No quarterly earnings. | |||||||
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| No annual earnings. | |||||
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual | 5.936 | 21.69 | 22.374 | 21.246 | 13.229 | 4.518 | -32.646 | -5.99 | -5.282 |
|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| EPS, quarterly | |||||||||
| Period | |||||||||
| Sales, annual | 22.537 | 50.369 | 46.097 | 50.033 | 57.1 | 64.855 | 46.471 | 25.098 | 37.919 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Sales, quarterly | |||||||||
| Period | |||||||||
| Shares, annual | 0.238 | 0.238 | 0.238 | 0.238 | 0.238 | 0.238 | 0.238 | 0.241 | 6.687 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Shares, quarterly | |||||||||
| Period |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 47.90 | 37.92 | 25.10 | 46.47 | 64.86 | 57.10 | 50.03 | 46.10 | 50.37 |
| Cost of Goods Sold Incl. D&A | 41.77 | 33.07 | 22.22 | 45.86 | 59.87 | 52.72 | 43.66 | 37.60 | 42.24 |
| Gross Profit | 6.13 | 4.85 | 2.88 | 0.61 | 4.98 | 4.37 | 6.37 | 8.49 | 8.13 |
| Selling, General and Administrative Excl. Other | 17.36 | 17.43 | 3.44 | 3.22 | 2.88 | 1.99 | 1.56 | 2.31 | 2.16 |
| Research and Development | 0.39 | 0.67 | 1.36 | 0.57 | 1.22 | 0.01 | 0.05 | 0.04 | 0.17 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Operating Income | -11.22 | -12.58 | -0.56 | -2.61 | 2.10 | 2.39 | 4.81 | 6.18 | 5.97 |
| Interest Expense | - | - | 0.64 | - | - | 0.06 | 0.24 | 0.22 | 0.22 |
| Unusual Expense | 4.16 | 7.70 | 0.82 | 5.53 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Net Income Before Taxes | -16.78 | -19.94 | -2.14 | -7.90 | 1.56 | 3.36 | 5.81 | 6.94 | 6.15 |
| Income Taxes | 4.83 | 0.28 | -0.62 | 0.22 | 0.19 | 0.26 | 0.86 | 1.03 | 0.94 |
| Consolidated Net Income | -21.60 | -20.22 | -1.52 | -8.12 | 1.37 | 3.11 | 4.94 | 5.91 | 5.20 |
| Net Income From Continuing Operations | -21.18 | -19.94 | -1.44 | -7.78 | 1.08 | 3.15 | 5.06 | 5.33 | 5.17 |
| Net Income | -21.18 | -19.94 | -1.44 | -7.78 | 1.08 | 3.15 | 5.06 | 5.33 | 5.17 |
| EPS (Recurring) | -2.95 | -3.85 | -3.61 | -16.41 | 4.52 | 13.23 | 21.25 | 22.37 | 21.69 |
| EPS (Basic, Before Extraordinaries) | -4.80 | -5.28 | -5.99 | -32.65 | 4.52 | 13.23 | 21.25 | 22.37 | 21.69 |
| EPS (Diluted) | -4.80 | -5.28 | -5.99 | -32.65 | 4.52 | 13.23 | 21.25 | 22.37 | 21.69 |
| EBITDA | -9.25 | -11.12 | 0.67 | -1.47 | 3.35 | 3.65 | 5.98 | 7.37 | 7.23 |
| Non-Operating Income (Expense) | -1.38 | 0.34 | -0.11 | 0.23 | -0.54 | 1.03 | 1.24 | 0.99 | 0.39 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 8.09 | - | - | - | - | - | - | - |
| Price To Earnings Ratio | - | - | - | 2,845.37 | 5,754.78 | 6,667.47 | - | - | - |
| Price To Sales Ratio | 1.17 | 30.59 | 2.30 | 0.61 | 0.66 | 2.53 | - | - | - |
| Gross Margin | 12.81 | 12.79 | 11.47 | 1.31 | 7.68 | 7.66 | 12.73 | 18.42 | 16.15 |
| Operating Margin | -23.42 | -33.18 | -2.25 | -5.62 | 3.24 | 4.18 | 9.62 | 13.40 | 11.86 |
| Net Margin | -44.22 | -52.59 | -5.75 | -16.74 | 1.66 | 5.52 | 10.12 | 11.57 | 10.26 |
| Shares Outstanding | 6.69 | 6.69 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| Market Capitalization | 106.97 | 106.97 | 1,156.91 | 4,221.47 | 6,192.58 | 21,023.54 | 20,919.46 | - | - |
Income statement, quarterly
| Metric | 2026S1 | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 | 2022S2 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 24.30 | 23.61 | 14.31 | 12.54 | 12.56 | 17.31 | 29.16 | 32.77 |
| Cost of Goods Sold Incl. D&A | 20.94 | 20.83 | 12.24 | 10.52 | 11.70 | 18.77 | 27.09 | 30.07 |
| Gross Profit | 3.36 | 2.78 | 2.07 | 2.02 | 0.86 | -1.47 | 2.08 | 2.70 |
| Selling, General and Administrative Excl. Other | 4.23 | 13.12 | 4.31 | 1.90 | 1.54 | 1.35 | 1.86 | 1.83 |
| Research and Development | 0.24 | 0.14 | 0.53 | 0.89 | 0.47 | - | - | - |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -0.88 | -10.34 | -2.24 | 0.12 | -0.68 | -2.82 | 0.21 | 0.87 |
| Interest Expense | 0.01 | - | - | 0.70 | - | - | - | - |
| Unusual Expense | -0.10 | 4.27 | 3.43 | 1.89 | -1.07 | 5.53 | 0.00 | 0.00 |
| Net Income Before Taxes | -1.96 | -14.82 | -5.12 | -2.48 | 0.34 | -8.59 | 0.69 | 1.19 |
| Income Taxes | 0.25 | 4.57 | -4.30 | -0.63 | 0.01 | -0.03 | 0.25 | 0.07 |
| Consolidated Net Income | -2.21 | -19.39 | -0.83 | -1.85 | 0.33 | -8.56 | 0.44 | 1.12 |
| Net Income From Continuing Operations | -2.10 | -19.08 | -0.86 | -1.86 | 0.41 | -8.28 | 0.50 | 0.99 |
| Net Income | -2.10 | -19.08 | -0.86 | -1.86 | 0.41 | -8.28 | 0.50 | 0.99 |
| EPS (Recurring) | -0.35 | -3.77 | 1.46 | -2.23 | -1.39 | -18.49 | 2.08 | 4.15 |
| EPS (Basic, Before Extraordinaries) | -0.34 | -4.46 | -0.82 | -7.71 | 1.74 | -34.73 | 2.08 | 4.15 |
| EPS (Diluted) | -0.34 | -4.46 | -0.82 | -7.71 | 1.74 | -34.73 | 2.08 | 4.15 |
| EBITDA | 0.07 | -9.32 | -1.80 | 0.80 | -0.12 | -1.90 | 0.43 | 1.58 |
| Non-Operating Income (Expense) | -1.18 | -0.21 | 0.55 | -0.01 | -0.05 | -0.24 | 0.48 | 0.32 |
| Price To Earnings Ratio | - | - | - | - | - | 2,845.37 | 4,682.17 | 5,754.78 |
| Price To Sales Ratio | 1.17 | 34.62 | 13.47 | 2.30 | 0.83 | 0.61 | 0.76 | 0.66 |
| Gross Margin | 13.81 | 11.77 | 14.46 | 16.10 | 6.84 | -8.48 | 7.12 | 8.25 |
| Operating Margin | -3.61 | -43.81 | -15.64 | 0.92 | -5.41 | -16.30 | 0.72 | 2.67 |
| Net Margin | -8.66 | -80.82 | -6.02 | -14.82 | 3.30 | -47.82 | 1.70 | 3.02 |
| Shares Outstanding | 6.69 | 6.69 | 3.28 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| Market Capitalization | 106.97 | 56,512.51 | 33,366.62 | 1,156.91 | 3,699.59 | 4,221.47 | 6,946.58 | 6,192.58 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 10.82 | 18.14 | 22.42 | 14.98 | 12.61 | 11.87 | 4.59 | 5.62 | 5.87 |
| Short Term Receivables | 17.05 | 5.77 | 6.35 | 4.87 | 13.47 | 12.63 | 6.54 | 4.85 | 1.01 |
| Inventories | 23.68 | 5.85 | 5.70 | 10.09 | 13.88 | 12.49 | 13.48 | 11.24 | 14.64 |
| Other Current Assets | - | 0.00 | 0.04 | 0.09 | 0.41 | 0.15 | - | 0.46 | 0.44 |
| Total Current Assets | 51.55 | 29.77 | 34.51 | 30.03 | 40.37 | 37.13 | 24.62 | 22.17 | 21.96 |
| Net Property, Plant & Equipment | 15.07 | 14.91 | 12.71 | 12.29 | 11.48 | 7.66 | 7.67 | 8.49 | 8.84 |
| Total Investments and Advances | 11.50 | 3.36 | 0.61 | 20.09 | 20.96 | 0.54 | 0.54 | 0.41 | 0.16 |
| Intangible Assets | 355.34 | 4.54 | 3.42 | 1.73 | 1.93 | 1.88 | 1.83 | 1.96 | 2.07 |
| Deferred Tax Assets | 0.25 | 0.42 | 0.01 | 0.21 | 0.43 | 0.36 | 0.26 | 0.32 | 0.34 |
| Other Assets | 0.12 | 0.00 | 0.00 | 0.17 | 0.19 | 0.56 | 0.35 | 0.00 | 0.00 |
| Total Assets | 433.81 | 53.00 | 51.26 | 64.53 | 75.35 | 48.14 | 35.27 | 33.34 | 33.38 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.86 | 0.00 | 0.55 | 1.70 | 7.92 | 7.43 | 4.90 | 4.22 | 6.94 |
| Accounts Payable | 6.56 | 4.13 | 3.59 | 5.29 | 6.64 | 4.38 | 3.57 | 3.76 | 4.69 |
| Income Tax Payable | 0.91 | 0.00 | 0.13 | 0.14 | 0.15 | 0.63 | 0.28 | 1.20 | 0.60 |
| Other Current Liabilities | 32.28 | 4.65 | 2.39 | 2.05 | 3.46 | 5.98 | 2.91 | 5.11 | 5.74 |
| Total Current Liabilities | 41.60 | 8.78 | 6.66 | 9.18 | 18.17 | 18.42 | 11.66 | 14.29 | 17.97 |
| Long Term Debt | 0.08 | 0.00 | 0.02 | 0.07 | 0.11 | 0.16 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.33 | 1.76 |
| Total Liabilities | 41.68 | 8.78 | 6.68 | 9.25 | 18.28 | 18.58 | 11.66 | 15.62 | 19.73 |
| Non-Equity Reserves | 0.24 | 0.13 | 0.22 | 0.31 | 0.40 | 0.72 | 0.97 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 390.88 | 42.74 | 42.79 | 53.05 | 54.86 | 26.10 | 19.89 | 15.32 | 11.24 |
| Total Shareholders Equity | 390.88 | 42.74 | 42.79 | 53.05 | 54.86 | 26.10 | 19.89 | 15.32 | 11.24 |
| Accumulated Minority Interest | 1.02 | 1.35 | 1.56 | 1.91 | 1.81 | 2.74 | 2.74 | 2.40 | 2.41 |
| Total Equity | 391.90 | 44.09 | 44.35 | 54.96 | 56.67 | 28.84 | 22.64 | 17.72 | 13.66 |
| Total Liabilities & Stockholders Equity | 433.81 | 53.00 | 51.26 | 64.53 | 75.35 | 48.14 | 35.27 | 33.34 | 33.38 |
| Book Value Per Share | 58.45 | 177.45 | 179.55 | 222.60 | 230.18 | 109.50 | 83.47 | 64.29 | 47.17 |
| Tangible Book Value Per Share | 5.31 | 158.60 | 165.18 | 215.35 | 222.09 | 101.61 | 75.77 | 56.08 | 38.47 |
| Full-Time Employees | 471 | 323 | 298 | 344 | 280 | 292 | 280 | 292 | - |
| Price to Book Ratio | 0.13 | 197.30 | 79.88 | 116.73 | 383.23 | 388.70 | - | - | - |
| Return on Assets | -8.19 | -2.77 | -13.44 | 1.54 | 5.11 | 12.14 | 15.54 | 15.50 | - |
| Return on Equity | -9.20 | -3.37 | -16.24 | 2.00 | 7.79 | 22.02 | 30.28 | 38.92 | - |
| Return on Invested Capital | -5.10 | -3.38 | -18.17 | 2.03 | 5.74 | 19.29 | 26.80 | 33.74 | 12.58 |
| Quick Ratio | 0.67 | 2.73 | 4.33 | 2.17 | 1.46 | 1.34 | 0.96 | 0.77 | 0.41 |
| Current Ratio | 1.24 | 3.39 | 5.18 | 3.27 | 2.22 | 2.02 | 2.11 | 1.55 | 1.22 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -21.60 | -20.22 | -1.52 | -8.12 | 1.37 | 3.11 | 4.94 | 5.91 | 5.20 |
| Depreciation | 1.97 | 1.46 | 1.24 | 1.14 | 1.25 | 1.26 | 1.17 | 1.19 | 1.25 |
| Other Funds (Non Cash) | 16.95 | 19.40 | 0.50 | 5.98 | 1.10 | -0.31 | -0.16 | -0.41 | 0.21 |
| Funds from Operations | 2.13 | 0.82 | -0.19 | -0.80 | 3.90 | 4.02 | 5.86 | 6.75 | 6.69 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.04 | -3.19 | 0.79 | 1.11 | 8.75 | -3.67 | -0.79 | -7.69 | -2.24 |
| Income Taxes Payable | 0.49 | 0.58 | 0.10 | -0.61 | 0.58 | -1.14 | 0.99 | -0.83 | 0.65 |
| Cash from Operating Activities | 3.17 | -2.37 | 0.60 | 0.31 | 12.65 | 0.35 | 5.08 | -0.95 | 4.45 |
| Capital Expenditures | -1.68 | -2.19 | -3.93 | -3.71 | -3.26 | -3.49 | -0.46 | -0.62 | -1.12 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | -0.71 | 0.00 | -0.13 | 0.00 |
| Sale of Fixed Assets and Businesses | 2.40 | 2.39 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 1.91 | -0.37 | 4.86 | -1.00 | 0.00 | -20.00 | 0.08 | -0.05 | -0.28 |
| Purchase of Investments | 1.67 | -0.37 | -1.40 | -1.00 | 0.00 | -20.00 | 0.00 | -0.06 | -0.28 |
| Sale Or Maturity of Investments | 0.23 | 0.00 | 6.26 | 0.00 | 0.00 | 0.00 | 0.08 | 0.01 | 0.00 |
| Other Uses | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 2.60 | -0.16 | 0.93 | -4.69 | -3.26 | -24.20 | -0.38 | -0.80 | -1.39 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | -1.79 | 0.00 | 0.00 | 0.00 | 0.00 | -0.73 |
| Change in Capital Stock | -5.76 | 0.00 | 0.00 | 0.00 | 0.00 | 23.87 | 0.00 | 0.00 | 0.25 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | -5.76 | 0.00 | 0.00 | 0.00 | 0.00 | 23.87 | 0.00 | 0.00 | 0.25 |
| Proceedsfrom Stock Options | -5.76 | 0.00 | 0.00 | 0.00 | 0.00 | 23.87 | 0.00 | 0.00 | 0.25 |
| Issuance or Reduction of Debt, Net | 0.44 | 2.62 | -0.49 | -1.19 | -5.94 | 0.12 | 2.14 | 0.87 | -2.63 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -5.31 | 2.62 | -0.49 | -2.98 | -5.94 | 23.99 | 2.14 | 0.87 | -3.12 |
| Exchange Rate Effect | 0.36 | -0.08 | 1.31 | -0.15 | -1.09 | 0.60 | 0.43 | -0.16 | -0.17 |
| Net Change in Cash | 0.82 | 0.00 | 2.34 | -7.50 | 2.37 | 0.74 | 7.27 | -1.03 | -0.24 |
| Free Cash Flow | 1.46 | -4.44 | -2.25 | -1.54 | 9.42 | -3.15 | 4.63 | -1.56 | 3.33 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 38.45 | - | - | - | 4.52 | - | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.17 | -0.41 | 0.20 | 0.19 | -0.05 | -0.09 | 0.06 | 0.02 |
Balance sheet, quarterly
| Metric | 2026S1 | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 11.55 | 10.82 | 14.54 | 18.14 | 25.36 | 22.42 |
| Short Term Receivables | 11.99 | 17.05 | 16.83 | 5.77 | 2.72 | 6.35 |
| Inventories | 22.08 | 23.68 | 11.57 | 5.85 | 4.92 | 5.70 |
| Other Current Assets | 0.11 | - | - | 0.00 | 0.33 | 0.04 |
| Total Current Assets | 45.72 | 51.55 | 42.94 | 29.77 | 33.33 | 34.51 |
| Net Property, Plant & Equipment | 15.20 | 15.07 | 15.33 | 14.91 | 13.10 | 12.71 |
| Total Investments and Advances | 10.40 | 11.50 | 4.20 | 3.36 | 0.00 | 0.61 |
| Intangible Assets | 364.62 | 355.34 | 139.83 | 4.54 | 3.42 | 3.42 |
| Deferred Tax Assets | 0.25 | 0.25 | 5.05 | 0.42 | 0.01 | 0.01 |
| Other Assets | 0.36 | 0.12 | 0.05 | 0.00 | 0.00 | 0.00 |
| Total Assets | 436.55 | 433.81 | 207.39 | 53.00 | 49.85 | 51.26 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.17 | 1.86 | 1.70 | 0.00 | 0.08 | 0.55 |
| Accounts Payable | 6.35 | 6.56 | 8.43 | 4.13 | 2.67 | 3.59 |
| Income Tax Payable | 1.01 | 0.91 | 0.48 | 0.00 | 0.30 | 0.13 |
| Other Current Liabilities | 28.03 | 32.28 | 12.98 | 4.65 | 1.67 | 2.39 |
| Total Current Liabilities | 36.57 | 41.60 | 23.59 | 8.78 | 4.73 | 6.66 |
| Long Term Debt | 0.00 | 0.08 | 0.08 | 0.00 | 0.02 | 0.02 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 36.57 | 41.68 | 23.66 | 8.78 | 4.75 | 6.68 |
| Non-Equity Reserves | 0.21 | 0.24 | 0.24 | 0.13 | 0.18 | 0.22 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 398.24 | 390.88 | 182.12 | 42.74 | 43.43 | 42.79 |
| Total Shareholders Equity | 398.24 | 390.88 | 182.12 | 42.74 | 43.43 | 42.79 |
| Accumulated Minority Interest | 1.53 | 1.02 | 1.37 | 1.35 | 1.49 | 1.56 |
| Total Equity | 399.77 | 391.90 | 183.49 | 44.09 | 44.92 | 44.35 |
| Total Liabilities & Stockholders Equity | 436.55 | 433.81 | 207.39 | 53.00 | 49.85 | 51.26 |
| Book Value Per Share | 59.55 | 58.45 | 55.58 | 177.45 | 182.23 | 179.55 |
| Tangible Book Value Per Share | 5.03 | 5.31 | 12.91 | 158.60 | 167.89 | 165.18 |
| Price to Book Ratio | 0.13 | 165.80 | 58.02 | 197.30 | 86.46 | 79.88 |
| Return on Assets | -6.58 | -8.19 | -2.11 | -2.77 | -13.78 | -13.44 |
| Return on Equity | -7.30 | -9.20 | -2.41 | -3.37 | -16.33 | -16.24 |
| Return on Invested Capital | -0.53 | -4.88 | -0.47 | -4.35 | 0.95 | -19.33 |
| Quick Ratio | 0.65 | 0.67 | 1.33 | 2.73 | 6.01 | 4.33 |
| Current Ratio | 1.25 | 1.24 | 1.82 | 3.39 | 7.05 | 5.18 |
Cash flow, quarterly
| Metric | 2026S1 | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 |
|---|---|---|---|---|---|---|
| Net Income | -2.21 | -19.39 | -0.83 | -1.85 | 0.33 | -8.56 |
| Depreciation | 0.95 | 1.02 | 0.44 | 0.68 | 0.55 | 0.92 |
| Other Funds (Non Cash) | 1.40 | 15.55 | 3.84 | 2.12 | -1.62 | 5.79 |
| Funds from Operations | 0.14 | 1.99 | -1.18 | 0.55 | -0.74 | -1.77 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 2.35 | -1.31 | -1.88 | -2.57 | 3.36 | 2.54 |
| Income Taxes Payable | 0.08 | 0.41 | 0.17 | 0.00 | 0.10 | -0.63 |
| Cash from Operating Activities | 2.49 | 0.68 | -3.06 | -2.02 | 2.62 | 0.76 |
| Capital Expenditures | -0.66 | -1.02 | -1.17 | -3.14 | -0.79 | -1.48 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 2.39 | 0.00 | 0.00 | 0.00 | 0.06 |
| Purchase or Sale of Investments | 0.18 | 1.72 | -2.09 | 3.40 | 1.46 | -1.00 |
| Purchase of Investments | -0.05 | 1.72 | -2.09 | -1.40 | 0.00 | -1.00 |
| Sale Or Maturity of Investments | 0.23 | 0.00 | 0.00 | 4.81 | 1.46 | 0.00 |
| Other Uses | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.50 | 3.10 | -3.26 | 0.26 | 0.67 | -2.42 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | -5.76 | 5.76 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | -5.76 | 5.76 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | -5.76 | 5.76 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.57 | 1.01 | 1.60 | -0.01 | -0.49 | -0.07 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -0.57 | -4.74 | 7.36 | -0.01 | -0.49 | -0.07 |
| Exchange Rate Effect | 0.28 | 0.09 | -0.17 | 1.24 | 0.07 | -0.50 |
| Net Change in Cash | 1.70 | -0.88 | 0.88 | -0.53 | 2.87 | -2.24 |
| Free Cash Flow | 1.82 | -0.36 | -4.07 | -4.08 | 1.83 | -0.74 |
| Price to Free Cash Flow | 38.45 | - | - | - | 22.58 | - |
Revenue breakdown
| China | 2024: 25.10M 2025: 37.92M |
|---|---|
| AI Solutions | 2025: 3.36M |
| Diversified Pharmaceutical and Allied Products | 2024: 25.10M 2025: 23.59M |
| Insurance Business | 2025: 10.96M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.20% | 0.0M | 3.7M | 8.23K |
| 2026-10-15 | 0.22% | 0.0M | 3.7M | 6.30K |
| 2026-09-30 | 0.10% | 0.0M | 3.7M | 8.37K |
| 2026-09-15 | 0.05% | 0.0M | 3.9M | 8.56K |
| 2026-08-31 | 0.15% | 0.0M | 3.9M | 13.97K |
| 2026-08-14 | 0.15% | 0.0M | 3.9M | 14.10K |
| 2026-07-31 | 0.24% | 0.0M | 2.9M | 14.44K |
| 2026-07-15 | 0.36% | 0.0M | 2.9M | 15.01K |
| 2026-06-30 | 0.21% | 0.0M | 2.8M | 12.93K |
| 2026-06-15 | 0.79% | 0.0M | 1.2M | 16.70K |
| 2026-05-29 | 0.70% | 0.0M | 1.2M | 11.13K |
| 2026-05-15 | 0.11% | 0.0M | 1.1M | 10.29K |
| 2026-04-30 | 0.14% | 0.0M | 1.1M | 8.80K |
| 2026-04-15 | 0.12% | 0.0M | 1.1M | 8.31K |
| 2026-03-31 | 0.31% | 0.0M | 1.1M | 6.52K |
| 2026-03-13 | 0.18% | 0.0M | 1.1M | 1.52K |
| 2026-02-27 | 0.20% | 0.0M | 1.1M | 1.49K |
| 2026-02-13 | 0.23% | 0.0M | 1.1M | 1.55K |
| 2026-01-30 | 0.20% | 0.0M | 1.1M | 572 |
| 2026-01-15 | 0.21% | 0.0M | 1.1M | 559 |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-09-24 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-24 | SEC |
| 2026-09-08 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-08 | SEC |
| 2026-08-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-28 | SEC |
| 2026-08-11 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-11 | SEC |
| 2026-07-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-30 | SEC |
| 2026-07-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-28 | SEC |
| 2026-07-21 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2025-09-30 | SEC |
| 2026-07-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-13 | SEC |
| 2026-06-17 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-17 | SEC |
| 2026-06-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-09 | SEC |
| 2026-05-18 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-18 | SEC |
| 2026-05-14 | 3 | Initial statement of beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-05-14 | 3 | Initial statement of beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-05-14 | 3 | Initial statement of beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-05-14 | 3 | Initial statement of beneficial ownership of securities | 2026-04-28 | SEC |
| 2026-05-07 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-07 | SEC |
| 2026-04-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-30 | SEC |
| 2026-04-13 | 3 | Initial statement of beneficial ownership of securities | 2026-04-13 | SEC |
| 2026-01-30 | NT 20-F | 2025-09-30 | SEC | |
| 2026-01-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-29 | SEC |
| 2025-12-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-12-18 | SEC |
| 2025-08-14 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-08-14 | SEC |
| 2025-07-24 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-03-31 | SEC |
| 2025-06-26 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-06-26 | SEC |
| 2025-06-03 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2025-05-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-05-28 | SEC |
| 2025-05-28 | SCHEDULE 13G | SEC | ||
| 2025-05-28 | SCHEDULE 13G | SEC | ||
| 2025-05-27 | SCHEDULE 13D/A | SEC | ||
| 2025-05-27 | SCHEDULE 13D | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 0.05% |
| XTX Topco Ltd | 0.03% |
| UBS Group AG | 0.03% |
| JANE STREET GROUP, LLC | 0.03% |
| Virtu Financial LLC | 0.03% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.02% |
| Ground Swell Capital, LLC | 0.01% |
| JPMORGAN CHASE & CO | 0.00% |
| ROYAL BANK OF CANADA | 0.00% |
| MORGAN STANLEY | 0.00% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index ETF | 0.01% |
| Fidelity Nasdaq Composite Index Fund | 0.01% |
OakChart. BGM. Cached 15 minutes.
Some panels did not load: ratings, insider.